Highlights CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
51.17 ^USD	-4.44%		-8.45%	-18.26%

May. 10	Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating	MT
May. 09	Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 Revenue $504,000	May. 08	MT
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach	May. 08	CI
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	Feb. 21	MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	Feb. 21	MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	Feb. 21	MT
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Crispr Therapeutics Announces European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY?	Feb. 13	CI
CRISPR Therapeutics Gets FDA Approval For Casgevy to Treat Transfusion-Dependent Beta Thalassemia	Jan. 16	MT
CRISPR Therapeutics Announces U.S. Food and Drug Administration Approval of CASGEVY? for the Treatment of Transfusion-Dependent Beta Thalassemia	Jan. 16	CI
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder	Jan. 16	RE
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery	Jan. 02	RE
CRISPR Therapeutics AG Adopts Positive Opinion for the Conditional Approval of Casgevy	Dec. 15	CI
CRISPR Therapeutics AG, CRISPR Therapeutics Limited, TRACR Hematology Ltd Enters into an Amendment to the Amended and Restated Joint Development and Commercialization Agreement with Vertex Pharmaceuticals ( Europe) Limited	Dec. 13	CI
CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States	Dec. 08	CI
US approves two gene therapies for sickle cell disease	Dec. 08	RE
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease	Dec. 04	CI
Vertex Pharmaceuticals, CRISPR Therapeutics Get UK Conditional Marketing Approval for Sickle Cell Disease Treatment	Nov. 16	MT
UK authorises gene therapy for blood disorders in world first	Nov. 16	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Highlights

Filters